Biological Activity
Orally active immunomodulatory agent that primarily targets macrophages. Inhibits TNF-α secretion via interference of macrophage toll-like receptor (TLR) 4 and TLR 2/6 signaling pathway. Also reduces the secretion of pro-inflammatory cytokines IL1-β, IL-10 and IFN-γ. Antidiabetogenic; prevents IL-β and IFN-γ-induced pancreatic islet cell death in vitro.
Technical Data
| M. Wt | 205.21 |
| Formula | C11H11NO3 |
| Storage | Store at +4°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 6501-72-0 |
| PubChem ID | 10798271 |
| InChI Key | MUFJHYRCIHHATF-UHFFFAOYSA-N |
| Smiles | O=C(CC1CC(C2=CC=CC=C2)=NO1)O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 20.52 | 100 | |
| water | 1.03 | 5mM with gentle warming |
Preparing Stock Solutions
The following data is based on the product molecular weight 205.21. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 4.87 mL | 24.37 mL | 48.73 mL |
| 5 mM | 0.97 mL | 4.87 mL | 9.75 mL |
| 10 mM | 0.49 mL | 2.44 mL | 4.87 mL |
| 50 mM | 0.1 mL | 0.49 mL | 0.97 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Stosic-Grujicic et al (2007) A potent immunomodulatory compound (S,R)-3-phenyl-4,5-dihydro-5-isoxasoleacetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of stre J.Pharmacol.Exp.Ther. 320 1038 PMID: 17148780
Stojanovic et al (2007) In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin.Immunol. 123 311 PMID: 17449326
Mangano et al (2008) In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Eur.J.Pharmacol. 586 313 PMID: 18374912
Keywords: GIT 27, supplier, Interfers, TLR4, TLR2/6, signalling, Immunomodulators, reduces, production, pro-inflammatory, cytokines, Toll-like, Receptors, TNF-α, TNF-alpha, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Cytokine, NF-κB, NF-kappaB, Signaling, Signalling, GI, Cytokines, Toll-like, Receptors, Cytokines, Tocris Bioscience
